PURPOSE: Patient-reported outcomes may help inform treatment choice in advanced/metastatic renal cell carcinoma (RCC), particularly between approved targeted therapies with similar efficacy.
This double-blind cross-over study evaluated patient preference for pazopanib or sunitinib and the influence of health-related quality of life (HRQoL) and safety factors on their stated preference.
PATIENTS AND METHODS: Patients with metastatic RCC were randomly assigned to pazopanib 800 mg per day for 10 weeks, a 2-week washout, and then sunitinib 50 mg per day (4 weeks on, 2 weeks off, 4 weeks on) for 10 weeks, or the reverse sequence. The primary end point, patient preference for a specific treatment, was assessed by questionnaire at the end of the two treatment periods. Other end points and analyses included reasons for preference, physician preference, safety, and HRQoL.
RESULTS: Of 169 randomly assigned patients, 114 met the following prespecified modified intent-to-treat criteria for the primary analysis: exposure to both treatments, no disease progression before cross over, and completion of the preference questionnaire. Significantly more patients preferred pazopanib (70%) over sunitinib (22%); 8% expressed no preference (P < .001). All preplanned sensitivity analyses, including the intent-to-treat population, statistically favored pazopanib. Less fatigue and better overall quality of life were the main reasons for preferring pazopanib, with less diarrhea being the most cited reason for preferring sunitinib. Physicians also preferred pazopanib (61%) over sunitinib (22%); 17% expressed no preference. Adverse events were consistent with each drug's known profile. Pazopanib was superior to sunitinib in HRQoL measures evaluating fatigue, hand/foot soreness, and mouth/throat soreness.
CONCLUSION: This innovative cross-over trial demonstrated a significant patient preference for pazopanib over sunitinib, with HRQoL and safety as key influencing factors.
Written by:
Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. Are you the author?
Institut Gustave Roussy, Villejuif; Centre François Baclesse, Caen; Leon Berard Cancer Center, Lyon, France; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia; San Camillo Forlanini Hospital, Rome; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Helsinki University Central Hospital, Helsinki, Finland; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London; Cambridge University Health Partners, Cambridge; Royal Preston Hospital, Lancashire; Christie Cancer Research UK, Manchester; GlaxoSmithKline, Uxbridge, United Kingdom; Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany; GlaxoSmithKline, Collegeville, PA; Northwestern University Feinberg School of Medicine, Chicago, IL.
Reference: J Clin Oncol. 2014 May 10;32(14):1412-8.
doi: 10.1200/JCO.2013.50.8267
PubMed Abstract
PMID: 24687826
UroToday.com Renal Cancer Section
